Compare ACADIA Pharmaceuticals Inc. (ACAD) vs KKR & Co Inc (KKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs KKR & Co Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while KKR & Co Inc trades at $93.05 (market cap $85.42B). The key difference: KKR & Co Inc is far larger — about 19× ACADIA Pharmaceuticals Inc.'s market cap, and KKR & Co Inc pays a 0.79% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | KKR | |
|---|---|---|
Market Cap | $4.49B | $85.42B |
Sector | Health | Financials |
52-Week High | $28.06 | $152.16 |
52-Week Low | $20.06 | $83.88 |
Enterprise Value | $3.69B | $10.95B |
Dividend Yield | — | 0.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
KKR trades at $95.14, up 1.39% today, with a bullish technical outlook supported by moving averages. The stock shows strong analyst sentiment with 24 buy ratings and a consensus price target of $127.43. Recent developments include a $1.3 billion renewable energy platform in South Korea and a $4.2 billion acquisition of EDF Power Solutions' North American operations, highlighting strategic growth initiatives. Financials reveal a P/E of 32.64 and net income margin of 14.51%, with Q1 2026 EPS beating expectations at $1.39 versus $1.26 estimated.
The outlook for KKR is positive, driven by expansion in renewable energy and private credit leadership, though risks include integration challenges from acquisitions and market volatility. Earnings growth and strategic deals present upside potential, with the current price offering a 34% discount to the analyst target. Investors should monitor Q2 2026 results due July 30, 2026, for further catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
